Pneumocystis carinii pneumonia: therapy and prophylaxis.
about
Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitorsPneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugsExpression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductaseActivity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse modelAcquired immunodeficiency syndrome: more than a health-related dilemma.Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice.Prognostic factors influencing the outcome in pneumocystis carinii pneumonia in patients with AIDSPulmonary complications of AIDS: a clinical strategy.Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene.Preventing secondary infections among HIV-positive persons.Trimetrexate for Pneumocystis carinii pneumonia in patients with AIDS.Lethal exacerbation of Pneumocystis carinii pneumonia in severe combined immunodeficiency mice after infection by pneumonia virus of mice.Opportunistic protozoan infections in human immunodeficiency virus disease: review highlighting diagnostic and therapeutic aspectsComparative study of antipneumocystis agents in rats by using a Pneumocystis carinii-specific DNA probe to quantitate infectionAssessing HIV infection in primary care practice.Aerosolized pentamidine in HIV. Promising new treatment for Pneumocystis carinii pneumonia.Management of early HIV-1 infection in adults.Efficacy and effects on pulmonary function tests of weekly 600 mg aerosol pentamidine as prophylaxis against Pneumocystis carinii pneumonia.Pneumocystis prophylaxis for all, some, or no HIV-infected infants less than one year of age: A decision analysis approach.Alterations in cysteine proteinase content of rat lung associated with development of Pneumocystis carinii infection.Optimization of in situ hybridization for detection of viral genomes in cultured cells on 96-microwell plates: a cytomegalovirus model.Use of beta-1,3-glucan-specific antibody to study the cyst wall of Pneumocystis carinii and effects of pneumocandin B0 analog L-733,560.Therapeutic progress. IV: Treatment and prophylaxis of Pneumocystis carinii infection.Molecular docking towards drug discovery.In-vitro interaction of human macrophages with Pneumocystis carinii.Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS.Clindamycin/primaquine for treatment of Pneumocystis carinii pneumonia in AIDS.The outcome of mechanical ventilation in patients with an AIDS-associated primary episode of Pneumocystis carinii pneumonia.Efficacy of clindamycin/primaquine versus trimethoprim/sulfamethoxazole in primary treatment of Pneumocystis carinii pneumonia.Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children.Cloning and sequence of a beta-tubulin cDNA from Pneumocystis carinii: possible implications for drug therapy.
P2860
Q28331119-40E2F25C-7A93-4962-899C-675C33692C12Q28333677-3646497E-DBE1-4A25-A942-47D9674ED8C5Q28344866-5637FD52-7019-4EAD-A8D3-86705B4A9388Q28378635-1D8C823C-00AD-4FA4-B53B-212EABDFB3DEQ30383795-045750DE-D72A-4B27-A114-DF9E5F973972Q33594578-CC1A5B2C-25D8-4953-AD9A-B5D8AFA602ADQ33605024-97650297-E1E1-4C9D-AEC7-6CE5314709A3Q34103710-5897C924-D681-4F40-964A-302DF1479D17Q34317942-831CECC0-496B-47F9-AF25-7891B90036CDQ35055557-C9EC1223-0069-4BA6-A295-010E9C76528FQ35869078-9877EB9B-2A5F-4377-9050-1A0FA601F5A4Q36361643-09E345DA-098D-448A-86EC-F8FFA9FB374EQ37143771-0A8D8096-8161-4B26-88E9-C2B1D971742FQ37250058-8C7A2C39-7B2D-4644-AC52-99B98CCB8CC5Q37669841-9DEE64BB-9C45-4E65-BEDC-3298090EADF1Q38669908-3DEC8783-B1BB-44AA-BC55-191CC98880ABQ38701223-FCBD2D67-15B5-4419-9E64-C31D7028BFD4Q39324981-4F2A478A-1285-48E7-A837-BE3C97EADF7DQ40141479-22EBA041-B05B-4B55-9693-B771A89C1EDFQ40155580-1F740CF3-0C87-4D88-9BB9-CAD0841D8C36Q40213247-63579430-3E21-4926-A6BE-6DD611B7B52BQ40286543-27188993-F351-4947-BC71-BAF160411136Q40434099-ABD583D5-E9CA-4F6C-8EC0-39D0B39E75E3Q40947235-1C4DDC2A-0946-490A-BE5E-AFFF1740409CQ41167500-B9E8CD2C-D33F-482C-9357-E5716B75F2F8Q42624762-F498D216-2F29-476C-83F8-07799A6CD5C1Q44710569-07D9AD64-E9C3-41BB-9D67-85119E30D908Q44903890-44291A88-0996-4182-B687-2BDFE25720B6Q45300468-92C8EF07-8539-4144-B73B-57418375FD83Q47689257-ECB006C3-0475-4B7B-80F8-92C254DE5BB4Q48178660-BDF86748-3A42-4C13-9139-F108E292ADA6
P2860
Pneumocystis carinii pneumonia: therapy and prophylaxis.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
Pneumocystis carinii pneumonia: therapy and prophylaxis.
@en
Pneumocystis carinii pneumonia: therapy and prophylaxis.
@nl
type
label
Pneumocystis carinii pneumonia: therapy and prophylaxis.
@en
Pneumocystis carinii pneumonia: therapy and prophylaxis.
@nl
prefLabel
Pneumocystis carinii pneumonia: therapy and prophylaxis.
@en
Pneumocystis carinii pneumonia: therapy and prophylaxis.
@nl
P356
P1476
Pneumocystis carinii pneumonia: therapy and prophylaxis.
@en
P2093
P304
P356
10.1093/INFDIS/158.1.254
P407
P577
1988-07-01T00:00:00Z